| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12038-017-9665-X |
| P698 | PubMed publication ID | 28229976 |
| P2093 | author name string | Ashok Kumar Vaid | |
| Minish Jain | |||
| Bandana Sharan | |||
| Chaitanya Kumar | |||
| Poonamalle Parthasarathy Bapsy | |||
| Sakshi Kohli | |||
| Venkata Sathya Suresh Attili | |||
| P2860 | cites work | A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer | Q22001066 |
| Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA | Q22010440 | ||
| Antigen presentation and T cell stimulation by dendritic cells | Q22255632 | ||
| Natural selection of tumor variants in the generation of "tumor escape" phenotypes | Q24551158 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| mTOR regulates memory CD8 T-cell differentiation | Q24648624 | ||
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways | Q46365793 | ||
| Poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. | Q47735411 | ||
| Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege | Q47860342 | ||
| Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. | Q50457532 | ||
| The first 1000 dendritic cell vaccinees. | Q50736412 | ||
| Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer. | Q51035691 | ||
| Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses | Q52005024 | ||
| Distinct patterns and kinetics of chemokine production regulate dendritic cell function. | Q54093362 | ||
| Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation | Q59055770 | ||
| Dendritic cell-B-cell interaction: dendritic cells provide B cells with CD40-independent proliferation signals and CD40-dependent survival signals | Q61027295 | ||
| Early events in dendritic cell maturation induced by LPS | Q73205992 | ||
| In vivo generation of human dendritic cell subsets by Flt3 ligand | Q74055026 | ||
| Expansion of Immunostimulatory Dendritic Cells from Peripheral Blood of Patients with Cancer | Q77941438 | ||
| Generation of functionally mature dendritic cells from elutriated monocytes using polyinosinic : polycytidylic acid and soluble CD40 ligand for clinical application | Q81947651 | ||
| Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care | Q87120295 | ||
| Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283]. | Q24816432 | ||
| Engineering opportunities in cancer immunotherapy | Q26776373 | ||
| Adoptive T-cell therapy for cancer: The era of engineered T cells | Q26800611 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Regulation of cutaneous malignancy by gammadelta T cells | Q28188439 | ||
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| A human memory T cell subset with stem cell-like properties | Q28248395 | ||
| The future of immune checkpoint therapy | Q28259862 | ||
| EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation | Q28282903 | ||
| The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network | Q28485085 | ||
| Cancer immunotherapy via dendritic cells | Q29615444 | ||
| The immunobiology of cancer immunosurveillance and immunoediting | Q29616246 | ||
| Taking dendritic cells into medicine | Q29619243 | ||
| Molecular identification of a danger signal that alerts the immune system to dying cells | Q29619497 | ||
| Cancer immunotherapy comes of age | Q29619918 | ||
| Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo | Q30080006 | ||
| Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control | Q30311891 | ||
| Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma | Q30423599 | ||
| DCVax®-L--developed by Northwest Biotherapeutics | Q30875456 | ||
| Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines | Q33683185 | ||
| Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. | Q33799806 | ||
| Dendritic cells: immunological sentinels with a central role in health and disease. | Q33890355 | ||
| The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer | Q33939202 | ||
| Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells | Q34029001 | ||
| Effects of cytokines on the culture and differentiation of dendritic cells in vitro | Q34199832 | ||
| Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy). | Q34232474 | ||
| Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer | Q34362516 | ||
| Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer | Q34543188 | ||
| Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation | Q34611780 | ||
| Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. | Q34657638 | ||
| Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo | Q34666875 | ||
| Nature's TRAIL--on a path to cancer immunotherapy | Q35046572 | ||
| The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies | Q35207756 | ||
| Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity | Q40136235 | ||
| A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer | Q40170491 | ||
| Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity | Q40372686 | ||
| Efficient migration of dendritic cells toward lymph node chemokines and induction of T(H)1 responses require maturation stimulus and apoptotic cell interaction. | Q40420976 | ||
| Primary antitumor immune response mediated by CD4+ T cells | Q40444553 | ||
| Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. | Q40470967 | ||
| Autologous dendritic cell vaccines for non-small-cell lung cancer. | Q40535885 | ||
| Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide | Q40724059 | ||
| Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein | Q40903376 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. | Q40928292 | ||
| Human Tumor Antigens and Cancer Immunotherapy | Q41533232 | ||
| T cell responses: naive to memory and everything in between | Q42727084 | ||
| Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites | Q42971765 | ||
| Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity | Q43293818 | ||
| Phenotypic and functional differences between human dendritic cells derived in vitro from hematopoietic progenitors and from monocytes/macrophages. | Q43611931 | ||
| Targeting dendritic cells--why bother? | Q43892663 | ||
| A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer | Q44370683 | ||
| Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells | Q44662354 | ||
| Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. | Q44743006 | ||
| Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo | Q44771609 | ||
| Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results | Q35504499 | ||
| Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer | Q35538449 | ||
| Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. | Q35563824 | ||
| TOR in the immune system | Q35621941 | ||
| NK cell compartments and their activation by dendritic cells | Q35634241 | ||
| Immunoregulatory T cells in tumor immunity | Q35692166 | ||
| Manipulating dendritic cell biology for the active immunotherapy of cancer | Q35825249 | ||
| Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. | Q35834680 | ||
| HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. | Q35899068 | ||
| Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease | Q35904666 | ||
| Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer | Q36228550 | ||
| Decreased tumor surveillance in perforin-deficient mice | Q36367528 | ||
| Maturation, activation, and protection of dendritic cells induced by double-stranded RNA | Q36367830 | ||
| Gamma delta T cells provide an early source of interferon gamma in tumor immunity | Q36371404 | ||
| The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer | Q36371644 | ||
| Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma | Q36407085 | ||
| Sipuleucel-T (APC8015) for prostate cancer | Q36613961 | ||
| Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination | Q36874310 | ||
| Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7 | Q36910715 | ||
| A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. | Q36958112 | ||
| Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors | Q36965879 | ||
| Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial | Q37024702 | ||
| Antigens for cancer immunotherapy. | Q37308133 | ||
| Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer | Q37394717 | ||
| Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma | Q37394755 | ||
| Immune parameters affecting the efficacy of chemotherapeutic regimens | Q37848665 | ||
| Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies | Q37875180 | ||
| Combining immunotherapy and targeted therapies in cancer treatment | Q37995939 | ||
| A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. | Q38036543 | ||
| Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives | Q38243924 | ||
| Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility | Q38974152 | ||
| Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. | Q39535140 | ||
| Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function | Q39692699 | ||
| Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients. | Q39765546 | ||
| P433 | issue | 1 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 161-173 | |
| P577 | publication date | 2017-03-01 | |
| P1433 | published in | Journal of Biosciences | Q2092222 |
| P1476 | title | Immune modulation by dendritic-cell-based cancer vaccines | |
| P478 | volume | 42 |
| Q91497028 | Cytolytic Activity of Effector T-lymphocytes Against Hepatocellular Carcinoma is Improved by Dendritic Cells Pulsed with Pooled Tumor Antigens |
| Q39415827 | Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. |
| Q91898387 | Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy |
Search more.